A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

In plain English

What this trial is testing

This study is testing Etrasimod (a drug) as a possible treatment. Condition(s) listed: Colitis, Ulcerative.

It is open-label: participants know what they are receiving.

Phase 2 studies test whether a treatment shows signs of working, and keep checking safety, in a larger group of people with the condition.

Who can join

• Ages 2 to 11
• Any sex

Some of the main requirements, copied from the record:

• Have a diagnosis of ulcerative colitis (UC) that is moderately to severely active Participants are permitted to be receiving a therapeutic dose of select UC therapies

There are also 1 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.

What's involved

• About 24 participants are expected to take part.
• Start date: 2026-05-28.
• Main results expected around 2030-09-08 (estimate from the record).
• 42 study sites listed (38 marked recruiting) in Australia, Canada, France, Germany and Israel and 5 more countries.

Main thing being measured

• Number and percent of enrolled participants with clinical remission based on Modified Mayo Score (MMS) at Week 52 (Week 52)

In the researchers’ words

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to < 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study…

This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.